Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
NOVATO, Calif., Jan. 04, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 7:30 am PT in San Francisco.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 844-758-7273
